NERVGEN PHARMA CORP. Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019
NERVGEN PHARMA CORP. (NGEN) reported Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 of 3.27 CAD/shares for the 12-month period ending 2025-12-31, per its 40-F filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 · last filed 2026-03-31
| Period end | Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 12 month |
|---|---|
| 2025-12-31 | 3.27 CAD/shares 40-F · filed 2026-03-31 |
| 2024-12-31 | 2.47 CAD/shares 40-F · filed 2026-03-31 |